On August 31, 2026, X-Cel Specialty Contacts and Essilor Custom Contacts jointly announced the U.S. launch of Lunara™, an overnight orthokeratology lens.

The product is FDA PMA-approved and is indicated for the temporary reduction of myopia up to −6.00 D, with astigmatism up to 1.75 D.

Lunara uses Optimum Infinite® (tisilfocon A), a rigid gas-permeable material with an oxygen permeability of 180 Dk.

The launch brings another high-Dk material option into the U.S. orthokeratology market and also highlights the continuing competition around material performance in overnight lens wear.

180 Dk High-Oxygen-Permeability Material

The central material feature of Lunara is its use of Optimum Infinite® (tisilfocon A), developed by Contamac.

According to Contamac, Optimum Infinite received FDA Premarket Approval for overnight orthokeratology use on February 10, 2026.

The material has an oxygen permeability of 180 Dk and is indicated for overnight use in the temporary reduction of myopia up to 6.00 diopters in eyes with astigmatism up to 1.75 diopters.

For overnight orthokeratology lenses, high oxygen permeability is particularly relevant because the cornea cannot obtain oxygen directly from ambient air while the eyelids are closed.

According to Contamac, Optimum Infinite was developed to combine high oxygen permeability with mechanical strength, dimensional stability and surface performance, supporting precision lens manufacturing and repeated wear.

Lunara is currently one of the commercial orthokeratology products using this material in the U.S. market.

How Does Lunara Compare With Existing High-Dk Ortho-K Products?

China’s orthokeratology market already includes several high-Dk products.

For example, products using materials with Dk values in the 180 range have entered commercialization, while some established imported products use materials with lower nominal Dk values.

Lunara’s 180 Dk material places it among the higher-Dk options currently available for overnight orthokeratology.

However, Dk should not be interpreted as a standalone measure of overall lens performance.

Clinical fitting also depends on factors including:

• lens geometry

• corneal shape

• centration

• tear exchange

• lens thickness

• surface characteristics

• manufacturing consistency

X-Cel states that Lunara combines the Optimum Infinite material with adjustable optic-zone and diameter options.

Its published fitting range includes:

• base curve: 6.50–10.50 mm

• diameter: 9.5–12.0 mm

• optic zone: 5.0–7.0 mm

• myopia range: −1.00 D to −6.00 D

The company positions these options as a way to give practitioners greater fitting flexibility while retaining familiar orthokeratology principles.

The Product Has Already Received FDA PMA Approval

The FDA PMA database lists Optimum Infinite (tisilfocon A) Orthokeratology Lenses II under PMA number P240045.

The application was submitted by Contamac and received FDA approval on February 10, 2026.

The approved indication covers overnight wear for the temporary reduction of myopia up to 6.00 D, with astigmatism up to 1.75 D.

X-Cel subsequently incorporated the material into Lunara and officially launched the product in the U.S. market on August 31.

This sequence is important because the regulatory approval applies to the orthokeratology lens system based on the material and its approved use, while the commercial launch reflects X-Cel and Essilor Custom Contacts bringing Lunara into clinical fitting channels.

Lunara Also Highlights the Competitive Pressure Facing the Chinese Ortho-K Market

The launch of Lunara is also relevant to the Chinese orthokeratology market.

China has one of the world’s largest myopia populations and has developed a substantial orthokeratology market over the past decade.

Domestic companies have also continued to improve materials, lens design and manufacturing capabilities.

The arrival of a new 180 Dk orthokeratology product in the U.S. reflects how global competition is continuing to move toward higher oxygen permeability, fitting flexibility and manufacturing consistency.

For Chinese companies, the significance is not simply whether one material has a higher numerical Dk value than another.

The broader competitive issues include:

• whether material performance can be translated into stable finished lenses

• whether lenses can maintain reproducible geometry and surface quality

• whether product design can support different corneal profiles

• whether clinical fitting systems and practitioner support are mature

• whether products can meet regulatory requirements across multiple markets

As the industry continues to develop, material specifications are likely to remain one part of a broader competition involving design, clinical performance and manufacturing.

Whether 180 Dk Becomes a New Benchmark Still Requires Clinical Observation

A higher Dk value can provide greater oxygen permeability, but whether 180 Dk becomes a broader benchmark for overnight orthokeratology will depend on clinical performance and market adoption.

The relevant questions extend beyond a single material parameter.

Practitioners will also consider fitting predictability, centration, comfort, corneal response, lens durability and long-term patient adherence.

For Lunara, its U.S. launch establishes another commercial option built around a high-Dk material platform.

Its actual position in the market will depend on how the product performs across routine clinical fitting and how practitioners respond to its combination of material properties, lens geometry and support services.

September 18, 2026